BACKGROUND: The instant blood-mediated inflammatory response (IBMIR) has been shown as a major factor that causes damage to transplanted islets. Withaferin A (WA), an inhibitor of nuclear factor (NF) κB, was shown to suppress the inflammatory response in islets and improve syngeneic islet graft survival in mice. We investigated how treating islets with NF-κB inhibitors affected IBMIR using an in vitro human autologous blood islet model. METHODS: Human islets were pretreated with or without NF-κB inhibitors WA or CAY10512 before mixing autologous blood in a miniaturized in vitro tube model. Plasma samples were collected at multiple time points and used for the measurement of C-peptide, proinsulin, thrombin-antithrombin (TAT) complex, and a panel of proinflammatory cytokines. Infiltration of neutrophils into islets was analyzed using immunohistochemistry. RESULTS: Rapid release of C-peptide and proinsulin was observed 3 hr after mixing islets and blood in the control group, but not in the NF-κB inhibitor-treated groups, whereas TAT levels were elevated in all three groups with a peak at 6 hr. Significant elevation of proinflammatory cytokines was observed in the control group after 3 hr, but not in the treatment groups. Significant inhibition of neutrophil infiltration was also observed in the WA group compared with the control (P<0.001) and CAY10512 (P<0.001) groups. CONCLUSIONS: A miniaturized in vitro tube model can be useful in investigating IBMIR. The presence of NF-κB inhibitor could alleviate IBMIR, thus improving the survival of transplanted islets. Protection of islets in the peritransplant phase may improve long-term graft outcomes.
BACKGROUND: The instant blood-mediated inflammatory response (IBMIR) has been shown as a major factor that causes damage to transplanted islets. Withaferin A (WA), an inhibitor of nuclear factor (NF) κB, was shown to suppress the inflammatory response in islets and improve syngeneic islet graft survival in mice. We investigated how treating islets with NF-κB inhibitors affected IBMIR using an in vitro human autologous blood islet model. METHODS:Human islets were pretreated with or without NF-κB inhibitors WA or CAY10512 before mixing autologous blood in a miniaturized in vitro tube model. Plasma samples were collected at multiple time points and used for the measurement of C-peptide, proinsulin, thrombin-antithrombin (TAT) complex, and a panel of proinflammatory cytokines. Infiltration of neutrophils into islets was analyzed using immunohistochemistry. RESULTS: Rapid release of C-peptide and proinsulin was observed 3 hr after mixing islets and blood in the control group, but not in the NF-κB inhibitor-treated groups, whereas TAT levels were elevated in all three groups with a peak at 6 hr. Significant elevation of proinflammatory cytokines was observed in the control group after 3 hr, but not in the treatment groups. Significant inhibition of neutrophil infiltration was also observed in the WA group compared with the control (P<0.001) and CAY10512 (P<0.001) groups. CONCLUSIONS: A miniaturized in vitro tube model can be useful in investigating IBMIR. The presence of NF-κB inhibitor could alleviate IBMIR, thus improving the survival of transplanted islets. Protection of islets in the peritransplant phase may improve long-term graft outcomes.
Authors: N Ishizuka; K Yagui; Y Tokuyama; K Yamada; Y Suzuki; J Miyazaki; N Hashimoto; H Makino; Y Saito; A Kanatsuka Journal: Metabolism Date: 1999-12 Impact factor: 8.694
Authors: David E R Sutherland; David M Radosevich; Melena D Bellin; Bernard J Hering; Gregory J Beilman; Ty B Dunn; Srinath Chinnakotla; Selwyn M Vickers; Barbara Bland; A N Balamurugan; Martin L Freeman; Timothy L Pruett Journal: J Am Coll Surg Date: 2012-03-06 Impact factor: 6.113
Authors: J A SoRelle; T Itoh; H Peng; M A Kanak; K Sugimoto; S Matsumoto; M F Levy; M C Lawrence; B Naziruddin Journal: Diabetologia Date: 2013-01-15 Impact factor: 10.122
Authors: L Moberg; H Johansson; A Lukinius; C Berne; A Foss; R Källen; Ø Østraat; K Salmela; A Tibell; G Tufveson; G Elgue; K Nilsson Ekdahl; O Korsgren; B Nilsson Journal: Lancet Date: 2002 Dec 21-28 Impact factor: 79.321
Authors: K P Samy; R P Davis; Q Gao; B M Martin; M Song; J Cano; A B Farris; A McDonald; E K Gall; C R Dove; F V Leopardi; T How; K D Williams; G R Devi; B H Collins; A D Kirk Journal: Am J Transplant Date: 2017-12-28 Impact factor: 8.086
Authors: Jordan Mattke; Srividya Vasu; Carly M Darden; Kenjiro Kumano; Michael C Lawrence; Bashoo Naziruddin Journal: Front Endocrinol (Lausanne) Date: 2021-08-10 Impact factor: 5.555
Authors: Susan J Burke; Krisztian Stadler; Danhong Lu; Evanna Gleason; Anna Han; Dallas R Donohoe; Richard C Rogers; Gerlinda E Hermann; Michael D Karlstad; J Jason Collier Journal: Am J Physiol Endocrinol Metab Date: 2015-08-25 Impact factor: 4.310
Authors: Natsuki Eguchi; Kimia Damyar; Michael Alexander; Donald Dafoe; Jonathan R T Lakey; Hirohito Ichii Journal: Antioxidants (Basel) Date: 2022-05-24
Authors: Mazhar A Kanak; Morihito Takita; Faisal Kunnathodi; Michael C Lawrence; Marlon F Levy; Bashoo Naziruddin Journal: Int J Endocrinol Date: 2014-04-30 Impact factor: 3.257
Authors: Juan S Danobeitia; Peter J Chlebeck; Inna Shokolenko; Xiaobo Ma; Glenn Wilson; Luis A Fernandez Journal: Cell Transplant Date: 2017-11 Impact factor: 4.064